Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WF-1042
- Development stage
- Preclinical
- Lead developer
- Staidson Biopharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral
01
Overview
WF-1042 is an investigational oral monoclonal antibody targeting Trophoblast cell-surface antigen 2 (TROP2), developed by Staidson Hongkong. TROP2 is a transmembrane glycoprotein that is highly expressed in various epithelial cancers, including breast, lung, and pancreatic tumors, where it promotes cell proliferation, survival, and metastasis. While monoclonal antibodies are typically administered parenterally due to their large molecular size and susceptibility to gastrointestinal degradation, WF-1042 is uniquely formulated as an oral capsule. This delivery method is intended to provide a more convenient administration route for patients. WF-1042 is currently in development for the treatment of solid tumors, aiming to inhibit tumor growth by binding to TROP2-expressing cells and potentially interfering with oncogenic signaling pathways or inducing immune-mediated cytotoxicity.
- Other names
- WF-1042 (capsule)WF-1042(胶囊)
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on WF-1042.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WF-1042.